...
机译:简短的Rituximab,Bendamustine,Mitoxantrone(R-BM)诱导,然后是Rituximab巩固在老年晚期卵泡淋巴瘤患者中:Bondazione Italiana Linfomi的II期研究(FIL)
SC Ematol AOU Citta Salute &
Sci Torino Turin Italy;
SC Ematol Azienda Osped Santi Antonio &
Biagio &
Alessandria Italy;
AO San Camillo Forlanini UOC Ematol &
Trapianto Cellule Staminali Rome Italy;
Univ Florence Dept Hematol Florence Italy;
Fdn IRCCS Policlin San Matteo Div Hematol Pavia Italy;
AOU Santa Maria Misericordia Clin Ematol &
Trapianto Midollo Osseo Udine Italy;
Univ Torino Dept Mol Biotechnol &
Hlth Sci Div Hematol Hematol 1 AOU Citta Salute &
Sci Torino;
AOU Policlin Vittorio Emanuele Ematol &
Trapianto Midollo Osseo PO Ferrarotto Alessi Catania;
SSD Ematol ASLTO4 Ivrea Italy;
FPO IRCCS Multidisciplinary Oncol Outpatient Clin Candiolo Canc Inst Turin Italy;
IRCCS Ist Nazl Tumori Div Hematol &
Stem Cell Transplantat Fdn Milan Italy;
AOU Maggiore Carita Hematol Novara Italy;
IRCCS Ist Nazl Tumori Div Hematol &
Stem Cell Transplantat Fdn Milan Italy;
Grande Osped Metropolitano Bianchi Melacrino More UOC Ematol Reggio Di Calabria Italy;
SC Ematol ASST Monza Monza Italy;
Univ Perugia Terni Italy;
ASST Spedali Civili SC Ematol Brescia Italy;
Univ Milan UOC Ematol Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan Italy;
UO Ematol Humanitas Clin &
Res Ctr IRCCS Milan Italy;
AOU Citta Salute &
Sci Torino Clin Epidemiol Unit CPO Piemonte Turin Italy;
AOU Citta Salute &
Sci Torino Clin Epidemiol Unit CPO Piemonte Turin Italy;
SC Ematol AOU Citta Salute &
Sci Torino Turin Italy;
follicular lymphoma; elderly; first-line treatment; chemoimmunotherapy; bendamustine;
机译:利妥昔单抗维持率与60岁以上晚期滤泡性淋巴瘤患者进行简短的一线R-FND化疗联合利妥昔单抗巩固治疗后的观察结果比较:Fondazione Italiana Linfomi进行的III期随机研究。
机译:利妥昔单抗,苯达莫司汀和阿糖胞苷(RBAC500)作为套剂对淋巴瘤的老年患者的诱导治疗:Fondazione Italiana Linfomi的2期研究的最终结果
机译:利妥昔单抗联合苯达莫司汀作为弱龄老年人(> 70岁)弥漫性大B细胞非霍奇金淋巴瘤患者的一线治疗:
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:利妥昔单抗联合苯达莫司汀作为弱龄老年人( 70岁)弥漫性大B细胞非霍奇金淋巴瘤患者的一线治疗:Fondazione Italiana Linfomi的II期多中心研究
机译:Rituximab Plus Bendamustine作为Frillual(> 70年)弥漫性大B细胞非霍奇金淋巴瘤患者的前线治疗患者:II期的Fondazione Italiana Linfomi的多中心研究